Companies in the News


  • BTRX-335140 Poised to Enter Phase 2 Efficacy Studies and BTRX-323511 to Enter IND-enabling Studies

  • Company Increasing Investment in Computational Psychiatry (CompPsych) Platform for Targeted CNS Therapeutics and Deprioritizing BTRX-246040 to Focus on Proprietary Programs

  • BlackThorn Participa...


  • Indigo has acquired TellusLabs, a leader in the use of satellite technology and artificial intelligence whose mission is to build a living map of the world's food supply.

  • TellusLabs' agricultural intelligence technology will integrate with Indigo's deep record of on-farm data, culminating in a pl...


  • Merger with OvaScience Closed 

  • Shares of Combined Company to Commence Trading on the Nasdaq Capital Market

  • Under New Symbol “MLND” on Monday, December 10th, 2018 

  • Proceeds of $85.4 Million to Fund Orphan Endocrine Pipeline 

  • Pivotal Phase 2b/3 Trial for Prader-Willi Syndrome Initiat...


  • Novel investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection

  • Subject dosing commenced

SAN FRANCISCO, Calif. and CAMBRIDGE, Mass. – November 26, 2018 - Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation...


SAN DIEGO, Oct. 16, 2018 /PRNewswire/ -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has entered into a clinical collaboration agreement with Merck (known as MSD outside the United States and Canada), t...


San Diego, CA – October 2, 2018 – Gossamer Bio, Inc. (“Gossamer Bio”) today announced that it has been named by FierceBiotech as one of 2018’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

“We are honored to be selected as a...


EMERYVILLE, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq:GRTS) today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. All of the shares of c...


  • Indigo Certified Crops™ is a new offer for U.S. growers, integrating the company’s microbial and digital technologies with the newly announced Indigo Marketplace™

  • The offer aims to increase grower profitability with higher yields and guaranteed premiums on grain sold through Indigo Marketplace™

  • ...


  • Indigo extends efforts to decommoditize agriculture with launch of Indigo Marketplace™, a digital platform for buying and selling grain

  • Indigo Marketplace has already connected thousands of U.S. growers and buyers, with billions of dollars in inventory and demand

  • Supporting Indigo’s mission...


ANN ARBOR, Mich., September 13, 2018 – Millendo Therapeutics, Inc., a clinicalstage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases, today announced the initiation of a Phase 2b clinical trial evaluating the efficacy and safety of its novel drug candidate, ne...

Please reload